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        Intrapartum Care of the Opiate Dependent Woman  
And her Newborn 
It is important that labor and delivery nurses are able to recognize and treat a patient 
under the influence of drugs, a patient withdrawing from drugs and those that are 
receiving treatment for drug dependence. The regularity of substance misuse among 
women is similar among different cultural and racial groups and is equally distributed 
among rural, suburban and urban areas (Goodman & Wolff, 2008). Substances that are 
commonly used include cocaine, amphetamines, opioids, alcohol, marijuana and tobacco. 
Polysubstance abuse is also common.  Urine drug tests may not detect intermittent drug 
use and do not routinely test for alcohol, the most commonly abused substance next to 
tobacco (Goodman & Wolff, 2008). Each of these drugs has negative effects on the 
pregnancy and the developing fetus. Complications include: miscarriage, preterm labor 
and delivery, low birth weight, IUGR, placental insufficiency, placental abruption, fetal 
distress, meconium stained fluid and stillbirth. If a patient comes to the unit displaying 
unusual behavior, agitation, dilated or constricted pupils, hypertension or hypotension, 
bradycardia or tachycardia, increased or decreased respirations or altered reflexes there 
should be further testing to rule out drug use as well as pregnancy complications like 
preeclampsia. This newsletter will discuss pharmacological treatments, pain relief options 
during labor, post-partum and the care of the newborn for those women who are 
experiencing dependence to illicit or prescribed opiates. 
  Table 1: Substance Dependence 
Includes the development of at least three of the 
following: 
1. Loss of control over the amount or duration 
of use 
2. Unsuccessful attempts to control use 
3. Change in usual activities as a result of use 
4. Continued use despite knowledge that 
physical or psychological harm will result 
5. Development of tolerance, necessitating 
larger amounts of the substance 
6. Development of withdrawal symptoms 
when abstaining 
                                                       (Goodman &Wolff, 2008)  
Heroin is the most commonly used illicit opiate. It can be injected, smoked or inhaled 
nasally. It crosses the placenta readily and has effects on the fetus within one hour after 
use (Keegan et al, 2010). Heroin has a short half- life and the user may need to take 
multiple doses daily to maintain the drug’s effects. Prescribed opioids, whose use may 
lead to dependence, include codeine, fentanyl, morphine, opium, oxycodone, meperidine, 
hydromorphone, hydrocodone, methadone and buprenorphine. These substances can be 
used in a variety of ways: swallowing, smoking, inhaling, injecting, chewing or used as 
suppositories (ACOG, 2010). When a pregnant woman has an opiate dependence the 
current standard of care is to transition to opiate maintenance therapy using methadone 
with buprenorphine as a second option (Goodman & Wolff, 2008) 
 
Methadone is a synthetic opioid that can be taken orally; it prevents the onset of 
withdrawal symptoms, eliminates drug cravings and blocks the euphoric effects of 
misused opiates. By maintaining a consistent maternal opiate level, methadone also 
protects the fetus from repeated episodes of withdrawal. Methadone dosages are usually 
started at 10-30 mg/day and are prescribed and dispensed by a registered substance abuse 
treatment program (ACOG, 2012). Dosages are adjusted throughout the pregnancy to 
avoid maternal and fetal withdrawal and are continued during labor and postpartum. 
Methadone has not been associated with any major maternal adverse effect but, 
methadone and opiate exposed newborns are predisposed to neonatal abstinence 
syndrome (NAS) that may require pharmacological therapy. 
 
Buprenorphine, when prescribed by accredited providers, is the only opioid approved 
for the treatment of opioid dependence in the office-based setting. Buprenorphine acts on 
the same receptors as heroin and morphine. It is available as a single-agent product or in 
a combined formulation with naloxone. The single-agent product is recommended during 
pregnancy to avoid exposing the fetus to naloxone. There are limited studies on the use of 
buprenorphine in pregnancy and the effects on the newborn. However, buprenorphine 
exposed newborns are quicker to recover from neonatal abstinence syndrome, requiring a 
shorter duration of treatment, less oral morphine to treat symptoms, and have shorter 
length of stay in the hospital (Maguire, 2014). 
  
Intrapartum, Post-Partum Care and Newborn Care 
The maintenance dose of methadone and buprenorphine do not provide analgesia or 
euphoria; they prevent opiate cravings. Therefore these women should receive the same 
options for pain relief as any other woman in labor. However Nubain (nalbuphine) and 
Stadol (butorphanol) should be avoided because they will cause acute withdrawal 
symptoms. Narcan (naloxone) should also be avoided for the same reason except for 
cases of opioid overdose. Morphine, Demerol and Fentanyl should be offered as well as 
epidural or spinal analgesia (Goff & O’Connor, 2007 and ACOG, 2012).  During the 
post-partum period, patients undergoing opioid maintenance treatment will require higher 
doses of opioids to achieve analgesia than other patients. For vaginal and post cesarean 
section deliveries, relief can be achieved with short acting opioids and IV non-steroidal 
antiinflammatory agents like Ketorolac (Toradol). Careful monitoring for over sedation 
should be done for those patients who receive opiates for pain relief. 
 
The pediatric staff should be notified of all narcotic-exposed infants. Methadone has a 
long half-life and therefore signs of neonatal abstinence syndrome (NAS) may not occur 
for several days or more after birth. It is likely that these infants will require monitoring 
for 4-7 days after birth. NAS is characterized by hyperactivity of the central and 
autonomic nervous systems and is seen in 55-94% of drug exposed newborns. Symptoms 
include irritability, poor sleep, tremors, hypertonia, frantic and uncoordinated sucking, 
sneezing, emesis, diarrhea, tachypnea, temperature instability and nasal stuffiness (Hudak 
& Tan, 2012). These newborns can also suffer from electrolyte imbalances, excessive 
hunger, disturbed sleep and poor tolerance to environmental changes (Goff & O’Connor, 
2007). Providers determine interventions for the newborn using the Finnegan Neonatal 
Abstinence Scoring Tool which allows objective assessment of withdrawal signs and 
symptoms in the newborn. The Finnegan score is a list of 21 signs and symptoms of 
withdrawal and is scored at 2 hours after birth and every 3-4 hours.  If newborns receive a 
score > 8 on three consecutive scores, pharmacological therapy is initiated; generally 
morphine is used to help ease the withdrawal symptoms. 
 
If the mother retains custody of her newborn, she should be educated about the ways to 
comfort the child that might be irritable and inconsolable. Mothers can also be 
encouraged to learn the signs of NAS.  Using the Finnegan scoring tool may be an 
effective educational tool. Regardless of whether or not the newborn needs 
pharmacological therapy for NAS, all drug-exposed newborns should receive 
nonpharmacologic support. This type of support should be taught to the parents or 
appointed caregivers (See Table 2).  The American Academy of Pediatrics, the American 
College of Obstetricians and Gynecologists and the Academy of Breastfeeding Medicine 
all agree that if the mother is stable on her methadone or buprenorphine maintenance 
therapy and is HIV negative, that she should be encouraged to breastfeed. Methadone and 
buprenorphine levels found in breast milk are relatively small. Breastfeeding encourages 
these mothers to take an active role in comforting their infant and lessen the severity of 
NAS. 
 
Table 2: Non Pharmacological Care of a Newborn with NAS 
Therapeutic handling  Swaddling or wrapping helps to control movements 
and provides comfort 
 Holding or lying in the “C” position increases the 
newborn’s ability to relax. 
 Skin to skin contact 
 Movement  Slow and rhythmic swaying 
 Approach the newborn slowly and in a calm fashion 
Feeding  Feed on demand 
 Breastfeeding  or pumping 
 May require supplementation due to unorganized 
suck 
Environment  Quiet environment with dim lights, soft voices 
 Tactile, visual and auditory stimuli should be 
introduced slowly 
       
 
 
Finnegan Scoring System 
System Symptoms Points Score 
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Excessive high pitched (or other) cry (< 5 min) 
Continuous high pitched (or other) cry (> 5 min) 
2 
3 
   
Sleep < 1 hour after feeding 
Sleep < 2 hours after feeding 
Sleep < 3 hours after feeding 
3 
2 
1 
   
Hyperactive Moro reflex 
Moderately hyperactive Moro reflex 
2 
3 
   
Mild tremors when disturbed 
Moderate-severe tremors when disturbed 
1 
2 
   
Mild tremors when undisturbed 
Moderate-severe tremors when undisturbed 
3 
4 
   
Increased muscle tone 1    
Excoriation (eg. Chin, knees, elbows, toes, nose) 1    
Myclonic jerks (twitching/jerking of limbs) 3    
Generalized convulsions 5    
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Sweating 1    
Hyperthermia (37.2 – 38.2°C) 
Hyperthermia (≥ 38.4°C) 
1 
2 
   
Frequent yawning (>3-4/interval) 1    
Molting 1    
Nasal stuffiness 1    
Frequent sneezing (> 3-4/interval) 1    
Nasal flaring 2    
Respiratory rate > 60/min 
Respiratory rate > 60/min with retractions 
1 
2 
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Excessive sucking 1    
Poor feeding (infrequent/uncoordinated suck) 2    
Regurgitation (≥2 times during/past feed) 
Projectile vomiting 
2 
3 
   
Loose stool  
Watery stool  
2 
3 
   
 TOTAL SCORE     
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